Match each pediatric infectious disease clinical scenario with the most appropriate antimicrobial management strategy, taking into account age-specific pharmacological safety profiles and treatment guidelines.
- A 3-day-old premature neonate develops temperature instability, apnea, and a bulging fontanelle; cerebrospinal fluid analysis indicates bacterial meningitis.Initiate intravenous ampicillin, gentamicin, and cefotaxime; avoid ceftriaxone due to the risk of biliary sludging and kernicterus.
- A 5-year-old boy presents in July with high fever, severe myalgias, and a petechial exanthem that originated on his wrists and ankles before spreading centrally.Prescribe a course of doxycycline immediately; do not substitute with other antibiotic classes despite the patient being under 8 years of age.
- A 15-day-old infant is hospitalized for severe paroxysmal coughing spells accompanied by cyanosis; complete blood count shows a leukocyte count of 40,000/mm³ with 82% lymphocytes.Administer an oral macrolide such as azithromycin; subsequently monitor the infant closely for the development of infantile hypertrophic pyloric stenosis.
- A 14-year-old girl with cystic fibrosis presents with an acute pulmonary exacerbation and increased purulent sputum; previous sputum cultures have predominantly grown Pseudomonas aeruginosa.Start combination therapy that may include a fluoroquinolone such as ciprofloxacin; use is justified in this context despite historical concerns of arthropathy.
Answer
The correct pairings successfully map each infectious scenario to its precise pharmacological intervention, recognizing specific pediatric contraindications (e.g., neonatal ceftriaxone) and critical indications for historically cautioned drugs (e.g., doxycycline in RMSF, fluoroquinolones in cystic fibrosis).
Each scenario requires applying specific pediatric pharmacological rules: avoiding ceftriaxone in neonates to prevent kernicterus, prioritizing doxycycline for RMSF regardless of age because it is life-saving and safe in short courses, monitoring for pyloric stenosis when using macrolides in infants under 1 month, and utilizing fluoroquinolones for cystic fibrosis exacerbations despite theoretical cartilage risks.
Step-by-Step Solution
Key Concept
Pediatric antimicrobial pharmacotherapy requires knowledge of age-specific adverse effects (kernicterus with ceftriaxone, pyloric stenosis with macrolides) and exceptions to general contraindications (doxycycline for RMSF, fluoroquinolones for cystic fibrosis).
Estimated Time:2m 30s